Stock

Immatics N.V. IMTX

$9.23-4.55%

All stocks Create account to unlock

Overview

IMTX market data

Price History

IMTX price chart

Valuation & Profitability

no valuation data

No Valuation Data Yet

Alpha Vantage and Twelve Data both returned no valuation metrics for IMTX. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.

Company news

3 captured

Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting · Jun 1, 2026, 12:15 PM

Immatics Announces Extended Data From Phaseb Clinicla Trial Evaluating Anzu-Cel PRAME TCR T-Cell Therapy In Heavily Pretreated Patients With Advanced Melanoma At ASCO Annual Meeting · Jun 1, 2026, 12:02 PM

Synovial Sarcoma Clinical Trial Pipeline Accelerates as 15+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight · May 28, 2026, 5:15 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock